web analytics

Nanomedicine Delivery Platform For Precision Targeting Of Pancreatic β-Cells

Published:
Lead Inventor: Yun Fang
Print or Save to PDF

SUMMARY

A nano-scale system delivers mRNA precisely to pancreatic β-cells, targeting both Type 1 and Type 2 diabetes preserving β-cell function and enhancing treatment specificity with minimal off-target effects

The Unmet Need: A transformative development in the management of diabetes

  • Advancements in biomedical research have increasingly focused on addressing conditions related to pancreatic β-cell dysfunction, a critical factor in diabetes management. The field has long sought targeted therapies to preserve or restore β-cell function, given their central role in maintaining glucose homeostasis. Achieving precision in treatment has become a necessity, as current clinical challenges underscore a significant unmet need in effectively managing both immune-mediated destruction and impaired β-cell performance without causing collateral damage.

  • Current treatment approaches often struggle with specificity, leading to widespread off-target effects that compromise overall patient health. For example, therapies that do not accurately target pancreatic β-cells can inadvertently affect surrounding tissues, resulting in systemic side effects and diminished therapeutic efficacy. Additionally, conventional strategies fail to address the dual challenges presented by the distinct pathologies of Type 1 and Type 2 diabetes, where β-cell loss and dysfunction each require tailored intervention strategies. This lack of precision limits the potential benefits of available treatments and highlights the critical need for solutions that combine targeted delivery with minimal adverse outcomes.

The proposed solution: Precise targeted delivery of therapeutic mRNA for the promotion of pancreatic beta cell preservation and regeneration with high specificity

  • The faculty inventor developed nano-scale carriers meticulously designed to deliver therapeutic agents directly to pancreatic β-cells, ensuring precision in both laboratory and living systems. This platform minimizes off-target effects, thereby reducing unwanted systemic side effects. The engineering allows for enhanced preservation and potential regeneration of β-cell function through exact placement of treatment agents.

ADVANTAGES

ADVANTAGES

  • Precise targeting of pancreatic β-cells, enhancing therapeutic efficacy

  • Minimization of off-target effects, reducing systemic side effects

  • Efficient functional mRNA delivery to support beta cell preservation and regeneration

APPLICATIONS

  • Type 1 and Type 2 diabetes

  • β-cell therapy/regeneration

  • mRNA delivery platform